Article
Nilotinib revisited in GIST: salvage use in patients with severe imatinib toxicity.
The oncologist - 9 Sept 2026
Falkenhorst Johanna, Hohenberger Peter, Mancino Giorgia, Scrima Andrea, Menge Franka, Fletcher Benjamin S, Reiff Carina, Lange Valerie, Hamacher Rainer, Bertram Stefanie, Rau Fiona M, Zaun Yasmin, Kaths Moritz, Treckmann Jürgen, Jakob Jens, Mühlenberg Thomas, Grunewald Susanne, Krzeciesa Dawid, Rauh Daniel, Bauer Sebastian
Abstract excerpt
BACKGROUND: Severe imatinib toxicity is a rare, but relevant event in GIST patients. Other approved treatments were not evaluated within a first-line setting and exhibit severe adverse events that limit QoL. Nilotinib was evaluated within this setting in GIST with a safety profile comparable to imatinib and effectiveness within KIT-exon-11-mutant GIST subgroup (ENESTg1). MATERIALS, PATIENTS, AND METHODS: This is...
Read the complete abstract on PubMedTopics
- Humans
- Pyrimidines
- Imatinib Mesylate
- Gastrointestinal Stromal Tumors
- Female